logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

ALK+ NSCLC: brigatinib tops crizotinib for PFS in ALTA-1L

Phase 3 trial also shows higher overall and intracranial objective response rates.